LATITUDE An Observational Study of Patient Choice and the Urethral Bulking Agent, Bulkamid®
Latitude-An Observational Study of Patient Choice and the Urethral Bulking Agent, Bulkamid®, Used for the First Line Treatment for Stress Urinary Incontinence and the Impact on a Subsequent Mid Urethral Sling
Sponsor: Contura
Listed as NCT03474653, this observational or N/A phase trial focuses on Stress Urinary Incontinence and Urinary Incontinence and remains ongoing. Sponsored by Contura, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Unknown
Status: Active Not Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
May 2023 — Jul 2024 [monthly]
Active Not Recruiting
-
May 2022 — May 2023 [monthly]
Active Not Recruiting
▶ Show 5 earlier versions
-
Mar 2021 — May 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2020 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Contura
- Manchester University NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .